title: Effect of combined treatment with imipramine and metyrapone on the immobility time, the activity of hypothalamo-pituitary-adrenocortical axis and immunological parameters in the forced swimming test in the rat.
abstract: Major depression is frequently associated with the hyperactivity of the hypothalamic-pituitary-adrenocortical axis, and glucocorticoid synthesis inhibitors have been shown to exert antidepressant action. The aim of the present study was to examine the effect of joint administration of metyrapone (50 mg/kg) and imipramine (5 and/or 10 mg/kg) on immobility time, plasma corticosterone concentration, the weight of spleens and thymuses and the proliferative activity of splenocytes in rats subjected to the forced swimming test--an animal model of depression. Metyrapone alone (50 mg/kg) reduced the immobility time of rats in the forced swimming test and decreased plasma corticosterone level, but did not change immunological parameters. Joint administration of metyrapone and imipramine (5 and 10 mg/kg) produced a more pronounced antidepressant-like effect than either of the drugs given alone. The forced swimming procedure significantly increased the proliferative activity of splenocytes, that parameter being reduced only by co-administration of metyrapone and imipramine. Joint administration of metyrapone and imipramine inhibited to a similar extend the corticosterone level as did treatment with metyrapone alone (about twofold); however, the plasma corticosterone level in animals treated with metyrapone and the higher dose of imipramine did not differ from the concentration of this steroid in control, not-stressed rats. The obtained results indicate that metyrapone potentiates the antidepressant-like activity of imipramine and exerts a beneficial effect on the stress-induced increase in plasma corticosterone concentration and the proliferative activity of splenocytes. These finding suggest that a combination of metyrapone and an antidepressant drug may be useful for the treatment drug-resistant depression and/or depression associated with a high cortisol level.
authors.affiliation: Department of Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, 31-343 Kraków, Poland.
authors.forename: Z
authors.initials: Z
authors.lastname: Rogóz
authors.forename: B
authors.initials: B
authors.lastname: Budziszewska
authors.forename: M
authors.initials: M
authors.lastname: Kubera
authors.forename: A
authors.initials: A
authors.lastname: Basta-Kaim
authors.forename: L
authors.initials: L
authors.lastname: Jaworska-Feil
authors.forename: G
authors.initials: G
authors.lastname: Skuza
authors.forename: W
authors.initials: W
authors.lastname: Lasoń
mesh_terms: D000818:Animals; D003345:Corticosterone / Q000097:blood; D003866:Depressive Disorder / Q000097:blood / Q000188:drug therapy*; D004359:Drug Therapy, Combination; D007030:Hypothalamo-Hypophyseal System / Q000187:drug effects* / Q000378:metabolism; D007099:Imipramine / Q000008:administration & dosage*; D007103:Immobilization / Q000379:methods; D008297:Male; D008797:Metyrapone / Q000008:administration & dosage*; D010913:Pituitary-Adrenal System / Q000187:drug effects* / Q000378:metabolism; D051381:Rats; D017208:Rats, Wistar; D013550:Swimming / Q000502:physiology
chemical_list: D007099:Imipramine; D003345:Corticosterone; D008797:Metyrapone